StreetInsider.com News Articles

H.C. Wainwright Reiterates Neutral Rating on Aldeyra Therapeutics (ALDX)

Wed, 30 Sep 2026 07:20:26 -0400

H.C. Wainwright analyst Matt Caufield reiterated a Neutral rating and $2.00 price target on Aldeyra Therapeutics (NASDAQ: ALDX).

The analyst commented: "Aldeyra announced its intent to submit a Formal Dispute Resolution Request (FDRR) to the FDA regarding the post-CRL regulatory path forward for novel RASP modulator Reproxalap, in the topical treatment of the signs and symptoms of dry eye disease (DED). We note this submission, anticipated 4Q26, coincides with plans to meet with the FDA’s Office of New Drugs (OND) and importantly follows the FDA’s most recent Complete Response Letter (CRL) related to the company’s NDA in dry eye disease. Notably,

Aldeyra to challenge FDA rejection of dry eye drug reproxalap

Tue, 29 Sep 2026 07:03:17 -0400

Aldeyra Therapeutics (Nasdaq: ALDX) announced plans to submit a Formal Dispute Resolution Request (FDRR) to the U.S. Food and Drug Administration appealing the rejection of its dry eye disease drug reproxalap.

The FDA issued a Complete Response Letter on March 16, 2026, denying approval of the New Drug Application for reproxalap, stating that the "totality of evidence from the completed clinical trials does not support the effectiveness of the product." It was the third such rejection Aldeyra has received for the drug, following an original NDA submission and two resubmissions.

The FDRR is expected to be reviewed by the FDA's Office of

Aldeyra to challenge FDA rejection of dry eye drug reproxalap

Tue, 29 Sep 2026 07:03:17 -0400

The FDRR is expected to be reviewed by the FDA's Office of

Form 8-K Aldeyra Therapeutics, For: Sep 29

Tue, 29 Sep 2026 07:01:00 -0400

si-local-file:///var/storage/secattach/20260929/27117222.html

Aldeyra Therapeutics Announces Intent to Submit Formal Dispute Resolution Request for Reproxalap to Treat Dry Eye Disease

Tue, 29 Sep 2026 07:00:00 -0400

CONCORD, Mass.--(BUSINESS WIRE)-- Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company devoted to discovering and developing innovative therapies designed to treat immune-mediated diseases, today announced intent to submit to the U.S. Food and Drug Administration (FDA) a Formal Dispute Resolution Request (FDRR) for reproxalap, an investigational drug candidate, for the treatment of dry eye disease. The FDRR, which is expected to be reviewed by the FDA’s Office of New Drugs (OND), is designed to appeal the March 16, 2026 Complete Response Letter that denied approval of a New Drug Application (NDA) for reproxalap for the treatment

Aldeyra Therapeutics Announces Intent to Submit Formal Dispute Resolution Request for Reproxalap to Treat Dry Eye Disease

Tue, 29 Sep 2026 07:00:00 -0400

Aldeyra Therapeutics to Host Regulatory Update Webcast

Mon, 28 Sep 2026 16:30:00 -0400

Event Scheduled for Tuesday, September 29 at 8:00 a.m. ET

CONCORD, Mass.--(BUSINESS WIRE)-- Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company devoted to discovering and developing innovative therapies designed to treat immune-mediated diseases, today announced that the company will host a regulatory update webcast on Tuesday, September 29, 2026, at 8:00 a.m. ET. The update will focus on reproxalap, an investigational drug for the treatment of dry eye disease.

A live audio webcast and slide presentation will be accessible from the “Investors & Media” section of the Aldeyra website at https://ir.aldeyra.com/ for 90

Aldeyra Therapeutics to Host Regulatory Update Webcast

Mon, 28 Sep 2026 16:30:00 -0400

Event Scheduled for Tuesday, September 29 at 8:00 a.m. ET

CONCORD, Mass.--(BUSINESS WIRE)-- Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company devoted to discovering and developing innovative therapies designed to treat immune-mediated diseases, today announced that the company will host a regulatory update webcast on Tuesday, September 29, 2026, at 8:00 a.m. ET. The update will focus on reproxalap, an investigational drug for the treatment of dry eye disease.

A live audio webcast and slide presentation will be accessible from the “Investors & Media” section of the Aldeyra website at https://ir.aldeyra.com/ for 90

Form SCHEDULE 13G Aldeyra Therapeutics, Filed by: AQR CAPITAL MANAGEMENT LLC

Wed, 12 Aug 2026 10:49:00 -0400

si-local-file:///var/storage/secattach/20260812/26910675.html

Form SCHEDULE 13G Aldeyra Therapeutics, Filed by: AQR CAPITAL MANAGEMENT LLC

Wed, 12 Aug 2026 10:49:00 -0400

si-local-file:///var/storage/secattach/20260812/26910675.html

Form 10-Q Aldeyra Therapeutics, For: Jun 30

Thu, 06 Aug 2026 16:02:00 -0400

si-local-file:///var/storage/secattach/20260806/26883352.html

Form 10-Q Aldeyra Therapeutics, For: Jun 30

Thu, 06 Aug 2026 16:02:00 -0400

si-local-file:///var/storage/secattach/20260806/26883352.html

Form 8-K Aldeyra Therapeutics, For: Jul 28

Thu, 30 Jul 2026 17:07:00 -0400

si-local-file:///var/storage/secattach/20260730/26844767.html

Form 8-K Aldeyra Therapeutics, For: Jul 28

Thu, 30 Jul 2026 17:07:00 -0400

si-local-file:///var/storage/secattach/20260730/26844767.html

Form SCHEDULE 13G/A Aldeyra Therapeutics, Filed by: BlackRock, Inc.

Mon, 27 Jul 2026 16:26:00 -0400

si-local-file:///var/storage/secattach/20260727/26819915.html

Form SCHEDULE 13G/A Aldeyra Therapeutics, Filed by: BlackRock, Inc.

Mon, 27 Jul 2026 16:26:00 -0400

si-local-file:///var/storage/secattach/20260727/26819915.html

Form 8-K Aldeyra Therapeutics, For: Jul 14

Wed, 15 Jul 2026 16:46:00 -0400

si-local-file:///var/storage/secattach/20260715/26774736.html

Form 8-K Aldeyra Therapeutics, For: Jul 14

Wed, 15 Jul 2026 16:46:00 -0400

si-local-file:///var/storage/secattach/20260715/26774736.html

Levicept Appoints Darlene Deptula-Hicks as CFO

Tue, 07 Jul 2026 04:00:00 -0400

Highly Experienced US-Based Public Markets Leader Strengthens Team as Company Drives Late Stage Development of LEVI-04 for Osteoarthritis

SANDWICH, United Kingdom, July 07, 2026 (GLOBE NEWSWIRE) -- Levicept Ltd, a biotechnology company focused on the development of LEVI-04, a first-in-class treatment for osteoarthritis (OA), today announces the appointment of Darlene Deptula-Hicks as Chief Financial Officer (CFO).

Darlene has a wealth of international experience in the biotechnology and pharmaceutical industries, a longstanding track record of raising capital in both private and public equity markets, and of strategic M&A. She is a Board Member and

Levicept Appoints Darlene Deptula-Hicks as CFO

Tue, 07 Jul 2026 04:00:00 -0400

Highly Experienced US-Based Public Markets Leader Strengthens Team as Company Drives Late Stage Development of LEVI-04 for Osteoarthritis

Form 4 Aldeyra Therapeutics, For: Jun 09 Filed by: Miller-Rich Nancy

Thu, 11 Jun 2026 16:27:00 -0400

si-local-file:///var/storage/secattach/20260611/26636086.html

Form 4 Aldeyra Therapeutics, For: Jun 09 Filed by: Miller-Rich Nancy

Thu, 11 Jun 2026 16:27:00 -0400

si-local-file:///var/storage/secattach/20260611/26636086.html

Form 4 Aldeyra Therapeutics, For: Jun 09 Filed by: DOUGLAS RICHARD

Thu, 11 Jun 2026 16:26:00 -0400

si-local-file:///var/storage/secattach/20260611/26636074.html

Form 4 Aldeyra Therapeutics, For: Jun 09 Filed by: DOUGLAS RICHARD

Thu, 11 Jun 2026 16:26:00 -0400

si-local-file:///var/storage/secattach/20260611/26636074.html

Form 4 Aldeyra Therapeutics, For: Jun 09 Filed by: Phillips Gary M.

Thu, 11 Jun 2026 16:26:00 -0400

si-local-file:///var/storage/secattach/20260611/26636062.html